Skip to main content
Premium Trial:

Request an Annual Quote

Industry Briefs : Mar 12, 2009


Gentel, Eprogen Commercializing Whole Proteome Arrays

Under a partnership announced this week, Gentel Biosciences and Eprogen will create products for the discovery of new autoantibody biomarkers using whole proteome microarrays.

Partitioned whole proteome arrays will be offered for fluorescence detection on Gentel's Path protein microarray slides and chromogenic detection on its Apix array system. Gentel will also process samples on whole proteome arrays for customers through its Symphony Array Services group.

Eprogen makes whole proteome microarrays from individual cell lines or tissue samples such as tumor biopsies using its ProteoSep fractionation technique.

Terms of the deal were not disclosed.

Novozymes Biopharma Uses GE Technology for Protein A Production

Novozymes Biopharma this week announced a licensing agreement calling for the use of GE Healthcare Life Sciences' technology for the production of native, animal-free protein A.

The protein is targeted to customers involved in the production of chromatography media.

Protein A is an active component in chromatography media used in the manufacture of antibodies. Novozyme's Protein A can be used to purify antibodies for biochemical analysis applications and drug production, the company said in a statement.

Proteome Sciences Receives ISO Certification

Proteome Sciences this week said it has received ISO 9001:2008 certification for its research, development, and production facilities in Frankfurt, Germany.

The accreditation is from the German Society for Certification of Management Systems and covers the company's biomarker activities, rapid assay development, chemical and peptide synthesis, and isobaric tagging development and production.

The Frankfurt facility was specifically designed to deliver a growing product line of isobaric Tandem Mass Tags for quantitative mass spectrometry and to perform biomarker work for customers.

PepScan Therapeutics Receives Milestone Payment from Genmab

Pepscan Therapeutics this week announced a milestone payment from Genmab arising from a collaboration to identify human antibodies against intractable targets.

Pepscan used its Chemically Linked Immunogenic Peptides on Scaffolds technology to generate multiple immunogens that mimic the protein targets to induce human antibodies against the intractable targets.

Under the agreement, Pepscan is eligible to receive payments from Genmab when it achieves certain development and regulatory milestones. Pepscan is also eligible for royalties on potential sales of therapeutics developed from the collaboration.

The amount of the payment was not disclosed.

APT Grants Stock Option to Officer

Advanced Proteome Therapeutics announced this week that it has granted stock options to an unnamed officer of the company to purchase up to 300,000 shares of the company's stocks.

The option is exercisable on or before March 10, 2014, at $.27 per share.

The move is pursuant to APT's stock option plan and subject to board approval and vesting provision contained in APT's stock option plan.

AnaSpec, BioPike Enter Distribution Deal

BioPike will distribute AnaSpec's catalog and custom product throughout China under a non-exclusive agreement announced this week.

Terms of the deal were not disclosed.